Immunotoxicity screening and immunomodulatory effects of 1-(4-hydroxytridecyloxy) pentadecan-4-ol isolated from Boerhavia erecta L., Nyctaginaceae, in BALB/c mice

The aim of the present study was to screen immunotoxicity and assess in vivo immunomodulatory activity of an active fraction of Boerhavia erecta (BE) having 1-(4-hydroxytrdecyloxy) pentadecan-4-ol. A total of 60 female BALB/c mice were randomly divided into six experimental groups (n = 10), Group 1 (vehicle control), Group 2 (250 mg/kg), Group 3 (500 mg/kg), Group 4 (1000 mg/kg), Group 5 (vehicle recovery) and Group 6 (high dose recovery). Clinical laboratory investigations (hematology, biochemistry), immunoglobulins (IgA, IgE & IgG), histopathology, gross pathology, necropsy were performed on day 28 for the first 4 groups and on day 56 n recovery groups (5 and 6). For immunomodulatory studies, plaque forming cell response to check humoral immunity and Sheep Red Blood Corpuscles (SRBC) to cellular immunity was evaluated. immunotoxicity study results were normal with no statistically or clinically significant abnormal changes between the tested and recovery groups. BE extract with active fraction of the isolated compound does not have immunotoxicity effects but exhibited immunosuppression specific to cell-mediated immunity in female BALB/c mice

Immunotoxicity screening and immunomodulatory effects of 1-(4-hydroxytridecyloxy) pentadecan-4-ol isolated from Boerhavia erecta L., Nyctaginaceae, in BALB/c mice

The aim of the present study was to screen immunotoxicity and assess in vivo immunomodulatory activity of an active fraction of Boerhavia erecta (BE) having 1-(4-hydroxytrdecyloxy) pentadecan-4-ol. A total of 60 female BALB/c mice were randomly divided into six experimental groups (n = 10), Group 1 (vehicle control), Group 2 (250 mg/kg), Group 3 (500 mg/kg), Group 4 (1000 mg/kg), Group 5 (vehicle recovery) and Group 6 (high dose recovery). Clinical laboratory investigations (hematology, biochemistry), immunoglobulins (IgA, IgE & IgG), histopathology, gross pathology, necropsy were performed on day 28 for the first 4 groups and on day 56 n recovery groups (5 and 6). For immunomodulatory studies, plaque forming cell response to check humoral immunity and Sheep Red Blood Corpuscles (SRBC) to cellular immunity was evaluated. immunotoxicity study results were normal with no statistically or clinically significant abnormal changes between the tested and recovery groups. BE extract with active fraction of the isolated compound does not have immunotoxicity effects but exhibited immunosuppression specific to cell-mediated immunity in female BALB/c mice